NYSE: $PFE Positive Momentum in Vaccine Development Pfizer has officially announced encouraging results from a Phase 2 clinical trial for its latest investigational vaccine candidate: a 25-valent pneumococcal conjugate vaccine (PCV). This development marks a significant potential step forward in protecting infants and children from invasive pneumococcal disease, a condition that remains a global health…